Jian-Jian Li, M.D., Ph.D.


Director of Translational Research




Radiation Oncology



Radiation Oncology

Locations and Contact

Research II

Research II
4625 2nd Ave.
Sacramento, CA 95817

Get Directions

Additional Numbers

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Research/Academic Interests

Research interests include the study of the molecular mechanisms causing tumor resistance to radiation and chemotherapy. Specific tumor resistant signaling networks that are regulated by radiation induced metabolic reprogramming and tumor immunosuppressive factors are being investigated in an array of human cancers including breast, lung, prostate, brain and liver.

Additional projects are related to radiation-induced adaptive response in normal tissues and in the radiation-resistant cancer stem cells. The goal of these studies is to find therapeutic targets to enhance cancer cure rates by radiotherapy.


Radiation Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.S., Xi'an Medical College, Xi'an, China 1979

Medical School

M.D., The Fourth Military Medical University, Xi'an, China 1984

Other School

Ph.D., Radiation and Free Radical Biology, University of Iowa, Iowa City IA 1994


Surgery, Xi'an Railway Central Hospital, Xi'an, China 1979-1981


Molecular Carcinogenesis, National Institutes of Health, Frederick MD 1994-1998


Radiation Oncology, UC San Francisco, San Francisco CA 1988-1990

Seed for Success Award of Purdue University Provost Office, 2004

NIH Cancer Research Fellow Award (NIH-CRFA), National Cancer Institute, National Institutes of Health, 1998

NIH Fellows Award for Research Excellence (NIH-FARE), National Cancer Institute, National Institutes of Health, 1996

NIH Intramural Research Training Award (NIH-IRTA), National Cancer Institute, National Institutes of Health, 1995

Recipient of E. Roosevelt International Cancer Research Award by International Union Against Cancer, 1988

To see a complete list of Dr. Li's publications, please click here

Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, Hamsafar Y, Evans AC, Huang J, Zhou W, Lin X, Ye N, Wanggou S, Chen W, Jing D, Fragoso RC, Dugger BN, Wilson PF, Coleman MA, Xia S, Li X, Sun LQ, Monjazeb AM, Wang A, Murphy WJ, Kung HJ, Lam KS, Chen HW, Li JJ. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun. 2022 Mar 21;13(1):1511. 

Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020 Sep 14;11(1):4591. 

Li JJ. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy. iScience. 2020 Jun 26;23(6):101215. Epub 2020 May 30. Review.

Zhang L, Xie B, Qiu Y, Jing D, Zhang J, Duan Y, Li Z, Fan M, He J, Qiu Y, Tan R, Li JJ, Sun LQ. Rab25-Mediated EGFR Recycling Causes Tumor Acquired Radioresistance. iScience. 2020 Apr 24;23(4):100997. Epub 2020 Mar 20.

Huang J, Li JJ. Cell repopulation, rewiring metabolism, and immune regulation in cancer radiotherapy. Radiation Medicine and Protection. 2020 March; 1:24-30.